Bertrand Tombal is at the Service d'Urologie, Clinique universitaires Saint Luc, Avenue Hippocrate 10, B-1200 Brussels, Belgium.Robert J. van Soest is at the Department of Urology, Erasmus University Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands
Checking for direct PDF access through Ovid
Results of the STAMPEDE and LATITUDE trials, which investigated the addition of abiraterone and prednisone to androgen-deprivation therapy in advanced prostate cancer, have renewed interest in ‘complete androgen blockade’, a concept originally described by Fernand Labrie in the 1980s. However, whether this treatment regimen should become standard of care remains to be seen.Refers to James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med.http://dx.doi.org/10.1056/NEJMoa1702900 (2017) | Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med.http://dx.doi.org/10.1056/NEJMoa1704174 (2017).